Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Kestra Medical Technologies (NASDAQ:KMTS), a wearable medical device company, reported strong Q4 and FY2025 results. Q4 revenue reached $17.2 million, up 71% year-over-year, while FY25 revenue hit $59.8 million, a 115% increase from FY24. The company's ASSURE庐 cardiac recovery system saw 13,193 prescriptions in FY25, up 72% from the previous year.
Gross margins significantly improved to 44.3% in Q4 FY25 from 13.9% in the prior year, and 40.5% for FY25 compared to 1.3% in FY24. Despite growth, the company reported a GAAP net loss of $51.1 million in Q4 and $113.8 million for FY25. Looking ahead, Kestra projects FY26 revenue of $85 million, representing 42% growth.
[ "Revenue grew 115% year-over-year to $59.8 million in FY25", "Significant gross margin expansion to 40.5% in FY25 from 1.3% in FY24", "Strong prescription growth with 13,193 ASSURE庐 system prescriptions in FY25, up 72%", "Robust cash position of $237.6 million as of April 30, 2025", "Projected 42% revenue growth for FY26 with $85 million guidance" ]Kestra Medical Technologies (NASDAQ:KMTS), azienda specializzata in dispositivi medici indossabili, ha riportato risultati solidi per il quarto trimestre e l'intero anno fiscale 2025. I ricavi del quarto trimestre hanno raggiunto 17,2 milioni di dollari, con un aumento del 71% rispetto all'anno precedente, mentre i ricavi dell'anno fiscale 2025 sono stati di 59,8 milioni di dollari, segnando un incremento del 115% rispetto al 2024. Il sistema di recupero cardiaco ASSURE庐 ha registrato 13.193 prescrizioni nel 2025, con una crescita del 72% rispetto all'anno precedente.
I margini lordi sono migliorati significativamente, passando al 44,3% nel quarto trimestre del 2025 rispetto al 13,9% dell'anno precedente, e al 40,5% per l'intero anno fiscale 2025 rispetto all'1,3% del 2024. Nonostante la crescita, l'azienda ha riportato una perdita netta GAAP di 51,1 milioni di dollari nel quarto trimestre e di 113,8 milioni di dollari per l'intero anno fiscale 2025. Guardando al futuro, Kestra prevede ricavi per l'anno fiscale 2026 pari a 85 milioni di dollari, con una crescita stimata del 42%.
- I ricavi sono cresciuti del 115% su base annua, raggiungendo 59,8 milioni di dollari nel 2025
- Espansione significativa dei margini lordi al 40,5% nel 2025, rispetto all'1,3% nel 2024
- Forte crescita delle prescrizioni con 13.193 prescrizioni del sistema ASSURE庐 nel 2025, in aumento del 72%
- Solida posizione di cassa pari a 237,6 milioni di dollari al 30 aprile 2025
- Crescita prevista del fatturato del 42% per il 2026 con una guida a 85 milioni di dollari
Kestra Medical Technologies (NASDAQ:KMTS), empresa de dispositivos m茅dicos port谩tiles, report贸 resultados s贸lidos en el cuarto trimestre y en el a帽o fiscal 2025. Los ingresos del cuarto trimestre alcanzaron 17,2 millones de d贸lares, un aumento del 71% interanual, mientras que los ingresos del a帽o fiscal 2025 fueron de 59,8 millones de d贸lares, un incremento del 115% respecto a 2024. El sistema de recuperaci贸n card铆aca ASSURE庐 registr贸 13.193 prescripciones en 2025, un aumento del 72% en comparaci贸n con el a帽o anterior.
Los m谩rgenes brutos mejoraron significativamente, alcanzando el 44,3% en el cuarto trimestre del 2025 frente al 13,9% del a帽o anterior, y el 40,5% para todo el a帽o fiscal 2025 en comparaci贸n con el 1,3% en 2024. A pesar del crecimiento, la compa帽铆a report贸 una p茅rdida neta GAAP de 51,1 millones de d贸lares en el cuarto trimestre y de 113,8 millones de d贸lares para todo el a帽o fiscal 2025. De cara al futuro, Kestra proyecta ingresos para el a帽o fiscal 2026 de 85 millones de d贸lares, lo que representa un crecimiento del 42%.
- Los ingresos crecieron un 115% interanual hasta 59,8 millones de d贸lares en 2025
- Expansi贸n significativa del margen bruto al 40,5% en 2025 desde el 1,3% en 2024
- Fuerte crecimiento en prescripciones con 13.193 prescripciones del sistema ASSURE庐 en 2025, un aumento del 72%
- Posici贸n de efectivo robusta de 237,6 millones de d贸lares al 30 de abril de 2025
- Crecimiento proyectado de ingresos del 42% para 2026 con una gu铆a de 85 millones de d贸lares
Kestra Medical Technologies (NASDAQ:KMTS)電� 鞗柎霟笖 鞚橂旮瓣赴 須岇偓搿�, 2025 須岅硠鞐半弰 4攵勱赴 氚� 鞐瓣皠 鞁れ爜鞐愳劀 臧曤牓頃� 靹标臣毳� 氤搓碃頄堨姷雼堧嫟. 4攵勱赴 毵れ稖鞚� 鞝勲厔 雽�牍� 71% 歃濌皜頃� 1,720毵� 雼煬鞐� 雼枅鞙茧┌, 2025 須岅硠鞐半弰 毵れ稖鞚� 鞝勲厔 雽�牍� 115% 歃濌皜頃� 5,980毵� 雼煬毳� 旮半頄堨姷雼堧嫟. 須岇偓鞚� ASSURE庐 鞁灔 須岆车 鞁滌姢韰滌潃 2025 須岅硠鞐半弰鞐� 13,193瓯挫潣 觳橂癌鞚� 旮半頃� 鞝勲厔 雽�牍� 72% 歃濌皜頄堨姷雼堧嫟.
齑� 毵堨鞚� 2025 須岅硠鞐半弰 4攵勱赴鞐� 鞝勲厔 13.9%鞐愳劀 韥矊 靸侅姽頃� 44.3%毳� 旮半頄堨溂氅�, 鞐瓣皠 旮办鞙茧霃� 2024雲� 1.3%鞐愳劀 40.5%搿� 韥矊 臧滌劆霅橃棃鞀惦媹雼�. 靹膘灔鞐愲弰 攵堦惮頃橁碃 須岇偓電� 4攵勱赴鞐� GAAP 旮办 靾滌啇鞁� 5,110毵� 雼煬, 鞐瓣皠鞙茧電� 1鞏� 1,380毵� 雼煬鞚� 靾滌啇鞁れ潉 氤搓碃頄堨姷雼堧嫟. 鞎烄溂搿� Kestra電� 2026 須岅硠鞐半弰 毵れ稖鞚� 8,500毵� 雼煬搿� 鞓堨儊頃橂┌ 42% 靹膘灔鞚� 旮半寑頃橁碃 鞛堨姷雼堧嫟.
- 2025 須岅硠鞐半弰 毵れ稖鞚� 鞝勲厔 雽�牍� 115% 靹膘灔頃橃棳 5,980毵� 雼煬 雼劚
- 齑� 毵堨鞚� 2024雲� 1.3%鞐愳劀 2025雲� 40.5%搿� 韥矊 頇曤寑
- ASSURE庐 鞁滌姢韰� 觳橂癌鞚� 2025雲勳棎 13,193瓯挫溂搿� 72% 歃濌皜
- 2025雲� 4鞗� 30鞚� 旮办 順勱笀 氤挫湢鞎� 2鞏� 3,760毵� 雼煬搿� 瓴碃頃� 鞛 靸來儨
- 2026 須岅硠鞐半弰 毵れ稖 4,200毵� 雼煬 歃濌皜 鞓堨儊, 8,500毵� 雼煬 臧�鞚措崢鞀� 鞝滌嫓
Kestra Medical Technologies (NASDAQ:KMTS), entreprise sp茅cialis茅e dans les dispositifs m茅dicaux portables, a annonc茅 de solides r茅sultats pour le quatri猫me trimestre et l'exercice 2025. Le chiffre d'affaires du quatri猫me trimestre a atteint 17,2 millions de dollars, en hausse de 71 % par rapport 脿 l'ann茅e pr茅c茅dente, tandis que le chiffre d'affaires de l'exercice 2025 a atteint 59,8 millions de dollars, soit une augmentation de 115 % par rapport 脿 2024. Le syst猫me de r茅cup茅ration cardiaque ASSURE庐 a enregistr茅 13 193 prescriptions en 2025, en hausse de 72 % par rapport 脿 l'ann茅e pr茅c茅dente.
Les marges brutes se sont nettement am茅lior茅es, passant 脿 44,3 % au quatri猫me trimestre 2025 contre 13,9 % l'ann茅e pr茅c茅dente, et 脿 40,5 % pour l'exercice 2025 contre 1,3 % en 2024. Malgr茅 cette croissance, la soci茅t茅 a enregistr茅 une perte nette GAAP de 51,1 millions de dollars au quatri猫me trimestre et de 113,8 millions de dollars pour l'ensemble de l'exercice 2025. Pour l'avenir, Kestra pr茅voit un chiffre d'affaires de 85 millions de dollars pour l'exercice 2026, soit une croissance de 42 %.
- Le chiffre d'affaires a augment茅 de 115 % en glissement annuel pour atteindre 59,8 millions de dollars en 2025
- Expansion significative de la marge brute 脿 40,5 % en 2025 contre 1,3 % en 2024
- Forte croissance des prescriptions avec 13 193 prescriptions du syst猫me ASSURE庐 en 2025, en hausse de 72 %
- Position de tr茅sorerie solide de 237,6 millions de dollars au 30 avril 2025
- Croissance pr茅vue du chiffre d'affaires de 42 % pour 2026 avec une pr茅vision 脿 85 millions de dollars
Kestra Medical Technologies (NASDAQ:KMTS), ein Unternehmen f眉r tragbare medizinische Ger盲te, meldete starke Ergebnisse f眉r das vierte Quartal und das Gesch盲ftsjahr 2025. Der Umsatz im vierten Quartal erreichte 17,2 Millionen US-Dollar, ein Anstieg von 71 % gegen眉ber dem Vorjahr, w盲hrend der Umsatz f眉r das Gesch盲ftsjahr 2025 59,8 Millionen US-Dollar erreichte, was einem Zuwachs von 115 % gegen眉ber 2024 entspricht. Das kardiale Erholungssystem ASSURE庐 verzeichnete im Gesch盲ftsjahr 2025 13.193 Verschreibungen, ein Plus von 72 % gegen眉ber dem Vorjahr.
Die Bruttomargen verbesserten sich deutlich auf 44,3 % im vierten Quartal 2025 gegen眉ber 13,9 % im Vorjahr und auf 40,5 % f眉r das Gesch盲ftsjahr 2025 im Vergleich zu 1,3 % im Jahr 2024. Trotz des Wachstums meldete das Unternehmen einen GAAP-Nettogewinnverlust von 51,1 Millionen US-Dollar im vierten Quartal und 113,8 Millionen US-Dollar f眉r das gesamte Gesch盲ftsjahr 2025. F眉r die Zukunft prognostiziert Kestra einen Umsatz von 85 Millionen US-Dollar im Gesch盲ftsjahr 2026, was einem Wachstum von 42 % entspricht.
- Umsatz wuchs im Gesch盲ftsjahr 2025 um 115 % auf 59,8 Millionen US-Dollar
- Deutliche Ausweitung der Bruttomarge auf 40,5 % im Gesch盲ftsjahr 2025 gegen眉ber 1,3 % im Jahr 2024
- Starkes Wachstum bei Verschreibungen mit 13.193 ASSURE庐-System-Verschreibungen im Gesch盲ftsjahr 2025, ein Anstieg von 72 %
- Robuste Barposition von 237,6 Millionen US-Dollar zum 30. April 2025
- Prognostiziertes Umsatzwachstum von 42 % f眉r das Gesch盲ftsjahr 2026 mit einer Umsatzprognose von 85 Millionen US-Dollar
- None.
- GAAP net loss increased to $113.8 million in FY25 from $94.1 million in FY24
- Operating expenses grew significantly to $130.6 million in FY25
- Adjusted EBITDA loss of $68.4 million in FY25
- High share-based compensation expense of $22.3 million in Q4 alone
Insights
Kestra shows triple-digit annual revenue growth and significant gross margin expansion despite continuing losses.
Kestra Medical Technologies has delivered exceptional growth metrics in their latest earnings report. With
The most impressive transformation appears in gross margins, which expanded dramatically from
The ASSURE庐 cardiac recovery system is gaining significant traction with 13,193 prescriptions written in FY25, up
Despite these positive indicators, Kestra remains significantly unprofitable with an FY25 GAAP net loss of
With
KIRKLAND, Wash., July 15, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the fourth quarter and fiscal year ended April 30, 2025.
Financial Highlights
- Reported revenue of
$17.2 million in Q4 FY25, an increase of71% compared to the prior year period. - Reported revenue of
$59.8 million in FY25, an increase of115% compared to FY24. - Generated gross margin of
44.3% in Q4 FY25 compared to13.9% in the prior year period. - Generated gross margin of
40.5% in FY25 compared to1.3% in FY24. - Initiated FY26 revenue guidance of
$85 million , an increase of42% compared to FY25.
鈥淲e capped an exciting year for Kestra with a very strong finish to our fiscal 2025. This quarter鈥檚 financial results reflect accelerating demand for our best-in-class cardiac recovery system as we continue to benefit from heightened prescriber awareness and the overwhelmingly positive experience patients are having with the ASSURE庐 system,鈥� said Brian Webster, President and CEO. 鈥淚n addition to our commercial execution, we are encouraged by the meaningful improvement in our gross margin, a result of the attractive unit economics and positive leverage inherent in our business model.鈥�
Mr. Webster continued, 鈥淚n fiscal year 2025, the ASSURE庐 system protected thousands of patients from sudden cardiac arrest, a testament to the dedication of our mission-driven team. We also made progress on several key operational objectives, including significant growth of our commercial organization and planned enhancements to our revenue cycle capabilities. We remain confident that our commitment to innovation and intense focus on prescriber and patient support will drive market expansion and advance Kestra鈥檚 pursuit of market leadership.鈥�
Fourth Quarter Fiscal 2025 Financial Results
- Total revenue was
$17.2 million in Q4, an increase of71% compared to the prior year period.- 3,903 prescriptions were written for the ASSURE庐 system in Q4, an increase of
43% compared to the prior year period. - Revenue growth was driven by a higher share of wallet with existing customers and activation of new accounts. Revenue also benefited from a higher mix of in-network patients and improvements in revenue cycle management capabilities.
- 3,903 prescriptions were written for the ASSURE庐 system in Q4, an increase of
- Gross profit was
$7.6 million in Q4 compared to$1.4 million in the prior year period.- Gross margin expanded to
44.3% in Q4 compared to13.9% in the prior year period, driven by volume leverage and a higher mix of in-network patients.
- Gross margin expanded to
- GAAP operating expenses were
$55.8 million in Q4 and included$22.3 million of share-based compensation expense and$3.8 million of professional services expenses related to the company鈥檚 IPO. GAAP operating expenses were$21.7 million in the prior year period.- As a result of the company鈥檚 IPO in March, share-based compensation expense in Q4 included one-time impacts from the accelerated vesting of incentive units and the issuance of stock options to Kestra team members.
- Excluding share-based compensation and professional services expenses related to the IPO, operating expenses were
$29.7 million in Q4 compared to$21.4 million in the prior year period. The increase was attributable to growth in expenses related to commercial and revenue cycle resources.
- GAAP net loss and comprehensive loss was
$51.1 million in Q4 compared to GAAP net loss and comprehensive loss of$22.3 million in the prior year period.- Adjusted EBITDA* loss was
$20.3 million in Q4 compared to an adjusted EBITDA loss of$16.5 million in the prior year period.
- Adjusted EBITDA* loss was
- Cash and cash equivalents totaled
$237.6 million as of April 30, 2025.
Fiscal Year 2025 Financial Results
- Total revenue was
$59.8 million in FY25, an increase of115% compared to FY24.- 13,193 prescriptions were written for the ASSURE庐 system in FY25, an increase of
72% compared to FY24.
- 13,193 prescriptions were written for the ASSURE庐 system in FY25, an increase of
- Gross profit was
$24.2 million in FY25 compared to$0.4 million in FY24.- Gross margin expanded to
40.5% in FY25 compared to1.3% in FY24.
- Gross margin expanded to
- GAAP operating expenses were
$130.6 million in FY25 compared to$85.4 million in FY24.- Excluding share-based compensation and professional services expenses related to the IPO, operating expenses were
$100.6 million in FY25 compared to$83.9 million in FY24.
- Excluding share-based compensation and professional services expenses related to the IPO, operating expenses were
- GAAP net loss and comprehensive loss was
$113.8 million in FY25 compared to GAAP net loss and comprehensive loss of$94.1 million in FY24.- Adjusted EBITDA* loss was
$68.4 million in FY25 compared to an Adjusted EBITDA loss of$72.0 million in FY24.
- Adjusted EBITDA* loss was
*Adjusted EBITDA is a non-GAAP financial measure. See 鈥淯se of Non-GAAP Financial Measures鈥� below for additional information. A reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure is included in this press release.
Fiscal Year 2026 Revenue Guidance
Kestra expects revenue of
Webcast and Conference Call
Kestra will host a conference call today at 4:30 p.m. ET to discuss fourth quarter and fiscal year 2025 financial results. A live and archived webcast of the event will be available in the 鈥淓vents鈥� section of the investor relations .
Use of Non-GAAP Financial Measures
This press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (鈥淕AAP鈥�), including Adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Kestra鈥檚 financial measures presented in this press release that are calculated and presented in accordance with GAAP.
Adjusted EBITDA, which is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, share-based compensation expense, and expenses related to Kestra鈥檚 initial public offering, is presented because management believes it allows investors to view the Company鈥檚 performance in a manner similar to the method used by management to evaluate the Company鈥檚 performance for both strategic and annual operating planning. Management believes that in order to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of Adjusted EBITDA, in addition to considering the Company鈥檚 GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of our ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare our period-over-period results.
The non-GAAP financial measures used by Kestra may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Kestra鈥檚 financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of Adjusted EBITDA reported in this press release to the most comparable GAAP measure for the respective periods appears in the table captioned 鈥淩econciliation of GAAP Net Income (Loss) to Adjusted EBITDA鈥� later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers.
Forward-Looking Statements
Except where otherwise noted, the information contained in this press release is as of July 15, 2025. Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as 鈥渨ill,鈥� 鈥渕ay,鈥� 鈥渃ould,鈥� 鈥渓ikely,鈥� 鈥渙ngoing,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥減roject,鈥� 鈥渋ntend,鈥� 鈥減lan,鈥� 鈥渂elieve,鈥� 鈥渁ssume,鈥� 鈥渢arget,鈥� 鈥渇orecast,鈥� 鈥済uidance,鈥� 鈥済oal,鈥� 鈥渙bjective,鈥� 鈥渁im,鈥� 鈥渟eek,鈥� 鈥減otential,鈥� 鈥渉ope鈥� and other words and terms of similar meaning. Kestra鈥檚 financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading 鈥淩isk Factors鈥� in our Registration Statement on Form S-1 and other filings filed or to be filed with the U.S. Securities and Exchange Commission (鈥淪EC鈥�), including our Annual Report on Form 10-K for the fiscal year ended April 30, 2025. These filings, when made, are available on the Investor Relations section of our website at and on the SEC鈥檚 website at .
About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit .
| KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS | |||||||
| 听 | |||||||
| (in thousands, except share and per share amounts) (unaudited) | |||||||
| 听 | |||||||
| 听 | April听30, | 听 | |||||
| 听 | 2025 | 听 | 听 | 2024 | 听 | ||
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Assets | 听 | 听 | 听 | 听 | 听 | ||
| Current assets | 听 | 听 | 听 | 听 | 听 | ||
| Cash and cash equivalents | $ | 237,595 | 听 | 听 | $ | 8,249 | 听 |
| Accounts receivable, net | 听 | 8,081 | 听 | 听 | 听 | 1,998 | 听 |
| Disposable medical equipment supplies | 听 | 6,572 | 听 | 听 | 听 | 3,290 | 听 |
| Prepaid expenses and other current assets | 听 | 3,080 | 听 | 听 | 听 | 1,370 | 听 |
| Total current assets | 听 | 255,328 | 听 | 听 | 听 | 14,907 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Right-of-use assets | 听 | 2,078 | 听 | 听 | 听 | 2,286 | 听 |
| Deposits | 听 | 2,021 | 听 | 听 | 听 | 1,710 | 听 |
| Restricted cash | 听 | 334 | 听 | 听 | 听 | 334 | 听 |
| Property and equipment, net | 听 | 34,830 | 听 | 听 | 听 | 26,105 | 听 |
| Other long-term assets | 听 | 1,153 | 听 | 听 | 听 | 607 | 听 |
| Total assets | $ | 295,744 | 听 | 听 | $ | 45,949 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Liabilities, Redeemable Preferred Stock and Shareholders鈥� Equity (Deficit) | 听 | 听 | 听 | 听 | 听 | ||
| Current liabilities | 听 | 听 | 听 | 听 | 听 | ||
| Accounts payable | $ | 23,961 | 听 | 听 | $ | 23,892 | 听 |
| Accrued liabilities | 听 | 13,829 | 听 | 听 | 听 | 9,079 | 听 |
| Operating lease liabilities, current portion | 听 | 187 | 听 | 听 | 听 | 鈥� | 听 |
| Total current liabilities | 听 | 37,977 | 听 | 听 | 听 | 32,971 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Operating lease liabilities, net of current portion | 听 | 3,026 | 听 | 听 | 听 | 2,633 | 听 |
| Warrant liabilities | 听 | 8,097 | 听 | 听 | 听 | 鈥� | 听 |
| Other long-term liabilities | 听 | 140 | 听 | 听 | 听 | 76 | 听 |
| Long-term debt, net | 听 | 41,098 | 听 | 听 | 听 | 42,536 | 听 |
| Total liabilities | 听 | 90,338 | 听 | 听 | 听 | 78,216 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Commitments and contingencies | 听 | 听 | 听 | 听 | 听 | ||
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Redeemable preferred stock, | 听 | 鈥� | 听 | 听 | 听 | 177,110 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Shareholders鈥� equity (deficit) | 听 | 听 | 听 | 听 | 听 | ||
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Common stock, | 听 | 鈥� | 听 | 听 | 听 | 1 | 听 |
| Common shares, | 听 | 51,349 | 听 | 听 | 听 | 鈥� | 听 |
| Additional paid-in capital | 听 | 674,306 | 听 | 听 | 听 | 197,057 | 听 |
| Accumulated deficit | 听 | (520,249 | ) | 听 | 听 | (406,435 | ) |
| Total shareholders鈥� equity (deficit) | 听 | 205,406 | 听 | 听 | 听 | (209,377 | ) |
| Total liabilities and shareholders鈥� equity (deficit) | $ | 295,744 | 听 | 听 | $ | 45,949 | 听 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||||||||||
| 听 | |||||||||||||||
| (in thousands, except share and per share amounts) (unaudited) | |||||||||||||||
| 听 | |||||||||||||||
| 听 | Three Months Ended April听30, | 听 | 听 | Year Ended April听30, | 听 | ||||||||||
| 听 | 2025 | 听 | 听 | 2024 | 听 | 听 | 2025 | 听 | 听 | 2024 | 听 | ||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Revenue | $ | 17,233 | 听 | 听 | $ | 10,054 | 听 | 听 | $ | 59,815 | 听 | 听 | $ | 27,814 | 听 |
| Cost of revenue | 听 | 9,600 | 听 | 听 | 听 | 8,657 | 听 | 听 | 听 | 35,605 | 听 | 听 | 听 | 27,452 | 听 |
| Gross profit | 听 | 7,633 | 听 | 听 | 听 | 1,397 | 听 | 听 | 听 | 24,210 | 听 | 听 | 听 | 362 | 听 |
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Research and development | 听 | 5,386 | 听 | 听 | 听 | 3,821 | 听 | 听 | 听 | 15,652 | 听 | 听 | 听 | 15,490 | 听 |
| Selling, general and administrative | 听 | 50,459 | 听 | 听 | 听 | 17,925 | 听 | 听 | 听 | 114,936 | 听 | 听 | 听 | 69,935 | 听 |
| Total operating expenses | 听 | 55,845 | 听 | 听 | 听 | 21,746 | 听 | 听 | 听 | 130,588 | 听 | 听 | 听 | 85,425 | 听 |
| Loss from operations | 听 | (48,212 | ) | 听 | 听 | (20,349 | ) | 听 | 听 | (106,378 | ) | 听 | 听 | (85,063 | ) |
| Other expense (income): | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Interest expense | 听 | 1,760 | 听 | 听 | 听 | 1,935 | 听 | 听 | 听 | 7,734 | 听 | 听 | 听 | 6,230 | 听 |
| Interest income | 听 | (1,656 | ) | 听 | 听 | 鈥� | 听 | 听 | 听 | (3,199 | ) | 听 | 听 | 鈥� | 听 |
| Other expense | 听 | 2,693 | 听 | 听 | 听 | 27 | 听 | 听 | 听 | 2,766 | 听 | 听 | 听 | 2,803 | 听 |
| Net loss before provision for income taxes | 听 | (51,009 | ) | 听 | 听 | (22,311 | ) | 听 | 听 | (113,679 | ) | 听 | 听 | (94,096 | ) |
| Provision for income taxes | 听 | 102 | 听 | 听 | 听 | (27 | ) | 听 | 听 | 135 | 听 | 听 | 听 | 24 | 听 |
| Net loss and comprehensive loss | 听 | (51,111 | ) | 听 | 听 | (22,284 | ) | 听 | 听 | (113,814 | ) | 听 | 听 | (94,120 | ) |
| Less: Undeclared preferred stock dividends | 听 | 3,291 | 听 | 听 | 听 | 1,994 | 听 | 听 | 听 | 12,321 | 听 | 听 | 听 | 6,721 | 听 |
| Net loss attributable to common shareholders, basic and diluted | $ | (54,402 | ) | 听 | $ | (24,278 | ) | 听 | $ | (126,135 | ) | 听 | $ | (100,841 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Net loss per share attributable to common shareholders, basic and diluted | $ | (2.21 | ) | 听 | $ | (1.22 | ) | 听 | $ | (5.13 | ) | 听 | $ | (5.07 | ) |
| Weighted-average shares of common shares outstanding, basic and diluted | 听 | 24,583,745 | 听 | 听 | 听 | 19,885,382 | 听 | 听 | 听 | 24,583,745 | 听 | 听 | 听 | 19,885,382 | 听 |
| RECONCILIATION OF GAAP NET LOSS AND COMPREHENSIVE LOSS TO ADJUSTED EBITDA | |||||||||||||||
| 听 | |||||||||||||||
| (in thousands) (unaudited) | |||||||||||||||
| 听 | |||||||||||||||
| 听 | Three Months Ended April听30, | 听 | 听 | Year Ended April听30, | 听 | ||||||||||
| 听 | 2025 | 听 | 听 | 2024 | 听 | 听 | 2025 | 听 | 听 | 2024 | 听 | ||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| GAAP Net loss and comprehensive loss | $ | (51,111 | ) | 听 | $ | (22,284 | ) | 听 | $ | (113,814 | ) | 听 | $ | (94,120 | ) |
| Non-GAAP Adjustments: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Interest expense | 听 | 1,760 | 听 | 听 | 听 | 1,935 | 听 | 听 | 听 | 7,734 | 听 | 听 | 听 | 6,230 | 听 |
| Interest income | 听 | (1,656 | ) | 听 | 听 | 鈥� | 听 | 听 | 听 | (3,199 | ) | 听 | 听 | 鈥� | 听 |
| Other expense | 听 | 2,693 | 听 | 听 | 听 | 27 | 听 | 听 | 听 | 2,766 | 听 | 听 | 听 | 2,803 | 听 |
| Provision for income taxes | 听 | 102 | 听 | 听 | 听 | (27 | ) | 听 | 听 | 135 | 听 | 听 | 听 | 24 | 听 |
| Depreciation expense | 听 | 1,836 | 听 | 听 | 听 | 3,502 | 听 | 听 | 听 | 7,968 | 听 | 听 | 听 | 11,560 | 听 |
| Share-based compensation expense | 听 | 22,313 | 听 | 听 | 听 | 389 | 听 | 听 | 听 | 24,271 | 听 | 听 | 听 | 1,488 | 听 |
| IPO expense | 听 | 3,809 | 听 | 听 | 听 | 鈥� | 听 | 听 | 听 | 5,736 | 听 | 听 | 听 | 鈥� | 听 |
| Adjusted EBITDA | $ | (20,254 | ) | 听 | $ | (16,458 | ) | 听 | $ | (68,403 | ) | 听 | $ | (72,015 | ) |
| 听 | |||||||||||||||
Investor contact Neil Bhalodkar [email protected]
FAQ
What were Kestra Medical Technologies' (KMTS) Q4 2025 earnings results?
How many ASSURE庐 system prescriptions did Kestra write in fiscal year 2025?
What is Kestra's (KMTS) revenue guidance for fiscal year 2026?
How much cash does Kestra Medical Technologies have on hand?
What drove Kestra's gross margin improvement in FY25?
